SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired common stock of MoonLake Immunotherapeutics between March 10, 2024, and September 29, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding the company's sole drug candidate, sonelokimab (SLK), which was claimed to be superior to competing monoclonal antibody drugs [3] Legal Proceedings - Investors wishing to serve as lead plaintiff must file papers by December 15, 2025, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5]